Neuropace/$NPCE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Neuropace
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Ticker
$NPCE
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
195
ISIN
US6412881053
Website
Neuropace Metrics
BasicAdvanced
$348M
-
-$0.83
2.05
-
Price and volume
Market cap
$348M
Beta
2.05
52-week high
$18.98
52-week low
$5.45
Average daily volume
431K
Financial strength
Current ratio
6.628
Quick ratio
5.555
Long term debt to equity
293.498
Total debt to equity
301.422
Interest coverage (TTM)
-2.22%
Profitability
EBITDA (TTM)
-19.062
Gross margin (TTM)
74.83%
Net profit margin (TTM)
-29.42%
Operating margin (TTM)
-22.86%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
-11.52%
Return on equity (TTM)
-128.49%
Valuation
Price to revenue (TTM)
3.763
Price to book
14.3
Price to tangible book (TTM)
14.3
Price to free cash flow (TTM)
-17.485
Free cash flow yield (TTM)
-5.72%
Free cash flow per share (TTM)
-60.62%
Growth
Revenue change (TTM)
22.05%
Earnings per share change (TTM)
-30.08%
3-year revenue growth (CAGR)
22.97%
3-year earnings per share growth (CAGR)
-21.48%
What the Analysts think about Neuropace
Analyst ratings (Buy, Hold, Sell) for Neuropace stock.
Bulls say / Bears say
NeuroPace reported a 28% year-over-year revenue increase to $21.1 million in Q3 2024, surpassing analyst estimates and indicating strong market demand for its RNS System. (gurufocus.com)
The company raised its full-year 2024 revenue guidance to $78–$80 million, reflecting confidence in sustained growth and operational efficiency. (stocktitan.net)
JPMorgan Chase & Co. increased its price target for NeuroPace from $9.00 to $14.00, assigning an 'overweight' rating, suggesting positive investor sentiment and potential stock appreciation. (marketbeat.com)
NeuroPace reported a net loss of $5.5 million in Q3 2024, indicating ongoing financial challenges despite revenue growth. (gurufocus.com)
The company's debt-to-equity ratio stands at 6.03, suggesting a high level of leverage that could pose financial risks. (marketbeat.com)
Wells Fargo & Company reduced its price target for NeuroPace from $15.00 to $13.00, indicating potential concerns about the company's future performance. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Neuropace Financial Performance
Revenues and expenses
Neuropace Earnings Performance
Company profitability
Neuropace News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Accesswire·4 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Accesswire·1 week ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect
Accesswire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neuropace stock?
Neuropace (NPCE) has a market cap of $348M as of June 21, 2025.
What is the P/E ratio for Neuropace stock?
The price to earnings (P/E) ratio for Neuropace (NPCE) stock is 0 as of June 21, 2025.
Does Neuropace stock pay dividends?
No, Neuropace (NPCE) stock does not pay dividends to its shareholders as of June 21, 2025.
When is the next Neuropace dividend payment date?
Neuropace (NPCE) stock does not pay dividends to its shareholders.
What is the beta indicator for Neuropace?
Neuropace (NPCE) has a beta rating of 2.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.